Venaxis, Inc. (APPY) - NASDAQ
  • Mar. 13, 2014, 9:17 AM
    | Mar. 13, 2014, 9:17 AM
  • Mar. 13, 2014, 7:41 AM
    • Venaxis' (APPY) APPY1 Test for identifying patients who are at low risk of appendicitis performed well in a pivotal trial, with sensitivity and negative predictive value results surpassing those in a pilot study.
    • Venaxis believes that the data is enough to receive FDA approval, and the company intends to file a 510(k) application in the next few weeks.
    • Shares surge 29% premarket. (PR)
    | Mar. 13, 2014, 7:41 AM | 3 Comments
  • Nov. 25, 2013, 2:52 PM
    • Shares of Venaxis (APPY +12%) are notably higher on the session.
    • Apparently helping the cause are analysts at Craig-Hallum, who are reportedly out with a $4 price target on the shares, representing upside of just under 141% from Friday's close.
    | Nov. 25, 2013, 2:52 PM | 1 Comment
  • Oct. 23, 2013, 9:29 AM
    • Venaxis (APPY) shares plunge 9.8% pre-market after it files a shelf to sell up to $20M in common stock. (S-3)
    • If carried out in full, the issuance would dilute shares outstanding by ~48%.
    | Oct. 23, 2013, 9:29 AM | 1 Comment
  • Sep. 26, 2013, 12:47 PM
    | Sep. 26, 2013, 12:47 PM
  • Jul. 15, 2013, 8:40 AM

    Venaxis (APPY) says the external Data & Safety Monitoring Board created for the trial of the company's APPY1 Test has recommended continuing the study based on two futility analyses that were carried out on 579 patients. The trial will enroll a total of 2,000 patients for the APPY1 Test, which identifies patients who are at low risk of appendicitis. Shares are -5.1%, possibly because Venaxis expects to complete recruitment by the end of 2013 rather than in August, as previously forecast, and file for FDA clearance in Q1 2014. (PR)

    | Jul. 15, 2013, 8:40 AM
  • May 24, 2013, 11:52 AM

    Venaxis (APPY -5%) slips today after pricing its 10M shares and related warrants to purchase 3.5M shares at a combined public price of $1.25 per share with an exercise price of $1.36. The offering is expected to close on May 30. Venaxis should realize approximately $11.1M in net proceeds from the sale, for which it intends to use primarily for funding of further clinical development and seeking FDA clearance for APPY1, as well as for initial commercialization of the drug in the U.S. and the E.U.

    | May 24, 2013, 11:52 AM
  • May 24, 2013, 9:10 AM
    Premarket gainers: BLOX +17%. IOC +15%. YGE +13%. P +11%. MRVL +5%.
    Losers: DF -52%. SHLD -16%. AVEO -15%. RSOL -13%. TITN -11%. APPY -7%. ANF -7%. CRM -5%.
    | May 24, 2013, 9:10 AM | 2 Comments
  • Mar. 26, 2013, 8:09 PM

    Venaxis Inc. (APPY) climbs in the post-trade session after providing an update on its clinical and commercial activities, reporting in its 10-K that it continues to enroll patients into its ongoing clinical study of APPY1, and it anticipates completing the study and potentially filing with the FDA for regulatory clearance by year end. Read more on its Business Update Conference Call Here: Business Update Transcript. Shares +5% AH.

    | Mar. 26, 2013, 8:09 PM
  • Feb. 25, 2013, 12:53 PM
    Midday top 10 gainers: ENMD +26%. OBCI +25%. GALT +19%. APPY +15%. NTWK +12%. BKS +12%. ZNGA +11%. HXM +10%. MGN +10%. CMGE +9%.
    Midday top 10 losers: AFFY -86%. CEDC -55%. DVAX -33%. GGS -31%. GMXR -24%. TROV -17%. EMITF -16%. ESI -14%. FRO -14%. XRSC -13%.
    | Feb. 25, 2013, 12:53 PM
  • Feb. 25, 2013, 10:43 AM

    Shares of beaten-down Venaxis (APPY +18.2%) are soaring today after Canaccord upgraded the stock to Buy and nearly tripled its price target to $7.00 from $2.50. The firm says that APPY's pursuit of a blood test to identify those at low risk for appendicitis is compelling, considering that appendicitis is the most-common non-traumatic childhood surgical disease. FDA approval could come before mid-2014 and the U.S. market alone could be nearly $700M.

    | Feb. 25, 2013, 10:43 AM
  • Feb. 7, 2013, 9:14 AM
    Premarket gainers: OXGN +31%. SUTR +29%. DV +18%. BIOL +9%. AAP +9%. ORLY +9%. APPY +7%. LF +6%.
    Losers: AKAM -18%. TQNT -11%. ARAY -9%. ANN -9%. GMCR -9%. NXST -6%. BBEP -6%. MWW -6%. BG -5%. ATML -5%.
    | Feb. 7, 2013, 9:14 AM
  • Jan. 8, 2013, 1:45 PM

    Venaxis (APPY -9.6%) slips today, despite its announcement late yesterday that European regulators have approved the company's blood-based appendicitis test APPY1. Initial sales are slated to begin during Q1 in key territories, including the UK, Italy, France, Germany and Benelux countries. The company expects to announce agreements with top EU distributors beginning in the first quarter 2013.

    | Jan. 8, 2013, 1:45 PM
  • Jan. 8, 2013, 9:10 AM
    Premarket gainers: PERI +19%. STSI +16%. CTIC +8%. PPHM +5%.
    Losers: GME -10%. APPY -6%. CY -6%. CLMT -5%.
    | Jan. 8, 2013, 9:10 AM
  • Dec. 21, 2012, 9:10 AM
    Premarket gainers: HALO +19%. CEMI +17%. ASCA +17%. APPY +14%. RHT +5%. PNK +5%. SHP +5%.
    Losers: ECTE -18%. RIMM -14%. ALU -7%.
    | Dec. 21, 2012, 9:10 AM | 1 Comment
  • Nov. 15, 2012, 10:30 AM

    AspenBio Pharma (APPY -13.8%) falls after pricing its previously announced secondary offering of 1.5M shares at $2.10 each, a 15% discount to Wednesday's close. The diagnostic-product developer has a 7.7M share float outstanding at the beginning of November.

    | Nov. 15, 2012, 10:30 AM
Company Description
Venaxis, Inc. is a vitro diagnostic company. The company focuses on the commercializing of its blood-based test to serve as an adjunctive test in the diagnosis and treatment of acute appendicitis in children adolescent and young adult patients. Venaxis was founded on July 24, 2000 and is... More
Sector: Healthcare
Industry: Diagnostic Substances
Country: United States